Ocumetics Technology Corp. reported encouraging one-month results from all patients in Group 1 of its first-in-human clinical study evaluating the Ocumetics Accommodating Intraocular Lens. The company completed Group 1 surgeries in August and September 2025, with all patients now showing Corrected Distance Visual Acuity ranging from 20/32 to 20/25 in their postoperative exams. These visual outcomes have met and in some cases exceeded internal expectations at this early stage of recovery according to company leadership.
Dean Burns, President and CEO of Ocumetics, expressed enthusiasm about the results, stating that every Group 1 patient is showing steady improvement with visual acuity. The results strongly reinforce the company's belief in the transformative potential of the Ocumetics Lens technology. Patients in Group 1 began the study with significantly impaired distance vision due to cataracts, making the visual gains seen as early as one month particularly significant for demonstrating the technology's effectiveness.
Dr. Doyle Stulting, Chief Medical Officer of Ocumetics, noted that achieving 20/32 or better vision this soon after surgery is remarkable. These data highlight the excellent optical quality and stability of the Ocumetics Lens and give the medical team great confidence as they advance to the next patient groups. The primary objectives of Group 1 were to confirm safety, evaluate surgical technique, and assess distance vision restoration, all of which have been successfully demonstrated according to the reported results.
The results demonstrate that the Ocumetics Lens performs as designed, providing safe implantation and strong optical performance. The company is developing an intraocular lens that fits within the natural lens compartment of the eye, potentially eliminating the need for corrective lenses. The technology is designed to allow the eye's natural muscle activity to shift focus from distance to near, providing clear vision at all distances without glasses or contact lenses. Ocumetics is now planning for Group 2 surgeries, with updates expected in the coming weeks as the clinical study progresses toward broader patient groups and further validates the technology's potential to revolutionize cataract treatment and vision correction.
